title: Big enough for an aromatase inhibitor? How adiposity affects male fertility.
abstract: Obesity is a pandemic and is associated with multiple medical problems including subfertility. Male obesity has been associated with altered semen parameters and reproductive hormonal levels, including a reduced testosterone:estradiol (T:E₂) ratio. Treatment methods employed for obesity-related male subfertility include gonadotropin administration, weight loss, and aromatase inhibitors. Letrozole is a highly effective nonsteroidal aromatase inhibitor that has been used to treat male subfertility in several case series with promising results. Adequately designed randomized controlled studies are needed to produce evidence-based data on the role of aromatase inhibitors in male subfertility management and evaluate the side-effect profile.
authors.affiliation: Department of Obstetrics and Gynecology, University of Colorado, Denver, Colorado, USA.
authors.forename: Sahar M
authors.initials: SM
authors.lastname: Stephens
authors.forename: Alex J
authors.initials: AJ
authors.lastname: Polotsky
mesh_terms: D050154:Adiposity; D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D007248:Infertility, Male / Q000150:complications / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D000077289:Letrozole; D008297:Male; D009570:Nitriles / Q000627:therapeutic use; D009765:Obesity / Q000503:physiopathology*; D012720:Severity of Illness Index; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D047072:Aromatase Inhibitors; D009570:Nitriles; D014230:Triazoles; D000077289:Letrozole